MX2013008851A - Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. - Google Patents

Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.

Info

Publication number
MX2013008851A
MX2013008851A MX2013008851A MX2013008851A MX2013008851A MX 2013008851 A MX2013008851 A MX 2013008851A MX 2013008851 A MX2013008851 A MX 2013008851A MX 2013008851 A MX2013008851 A MX 2013008851A MX 2013008851 A MX2013008851 A MX 2013008851A
Authority
MX
Mexico
Prior art keywords
methods
chronic inflammation
compostions
inflammatory diseases
treating chronic
Prior art date
Application number
MX2013008851A
Other languages
English (en)
Other versions
MX346224B (es
Inventor
John Brew
Robin Mark Bannister
Gregory Alan Stoloff
Suzanne Jane Dilly
Wilson Caparros-Wanderley
Gemma Szucs
Olga Pleguezuelos Mateo
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1101937.9A external-priority patent/GB201101937D0/en
Priority claimed from GBGB1113730.4A external-priority patent/GB201113730D0/en
Priority claimed from GBGB1113729.6A external-priority patent/GB201113729D0/en
Priority claimed from GB1113728.8A external-priority patent/GB2487808A/en
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of MX2013008851A publication Critical patent/MX2013008851A/es
Publication of MX346224B publication Critical patent/MX346224B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Fertilizers (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente especificación describe composiciones farmacéuticas, métodos para preparar tales composiciones farmacéuticas, y métodos y usos para tratar una inflamación crónica y/o una enfermedad inflamatoria en un individuo que usa dichas composiciones farmacéuticas.
MX2013008851A 2011-02-04 2012-02-03 Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. MX346224B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1101937.9A GB201101937D0 (en) 2011-02-04 2011-02-04 Method of preparing a composition
GBGB1113730.4A GB201113730D0 (en) 2011-08-10 2011-08-10 Solid dosage form
GBGB1113729.6A GB201113729D0 (en) 2011-08-10 2011-08-10 Hyperlipidaemia
GB1113728.8A GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol
PCT/GB2011/052115 WO2012056251A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
PCT/GB2012/050242 WO2012104655A2 (en) 2011-02-04 2012-02-03 Compostions and methods for treating chronic inflammation and inflammatory diseases

Publications (2)

Publication Number Publication Date
MX2013008851A true MX2013008851A (es) 2013-12-16
MX346224B MX346224B (es) 2017-03-10

Family

ID=46602107

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013008850A MX364229B (es) 2011-02-04 2012-02-03 Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2013008851A MX346224B (es) 2011-02-04 2012-02-03 Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013008850A MX364229B (es) 2011-02-04 2012-02-03 Composiciones y metodos para tratar enfermedades cardiovasculares.

Country Status (12)

Country Link
EP (4) EP2670390A2 (es)
JP (3) JP2014504629A (es)
CN (2) CN103391767B (es)
AU (2) AU2012213218C1 (es)
BR (2) BR112013019734A2 (es)
CA (2) CA2826452C (es)
ES (1) ES2981782T3 (es)
MX (2) MX364229B (es)
RU (3) RU2016138830A (es)
SG (3) SG192620A1 (es)
WO (2) WO2012104654A1 (es)
ZA (2) ZA201305783B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3300721T (pt) * 2003-11-20 2019-06-06 Novo Nordisk As Formulações peptidicas contendo propileno glicol que sao ideais para a produção e para utilizacao em dispositivos de injeção
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
CA2889035A1 (en) 2012-10-24 2014-05-01 Biocopea Limited Drug combinations and uses
CN104968330A (zh) * 2013-01-14 2015-10-07 因佛斯特医疗有限公司 用于治疗剧痛的组合物及方法
EP2943193A2 (en) 2013-01-14 2015-11-18 Health Clinics Limited Cancer drug and uses
RU2674982C2 (ru) * 2013-01-14 2018-12-14 ИнФерст Хэлткэр Лимитед Композиции твердых растворов и их применение при сердечно-сосудистом заболевании
MX366317B (es) * 2013-02-04 2019-07-03 Infirst Healthcare Ltd Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
KR101344218B1 (ko) * 2013-05-15 2013-12-20 충남대학교산학협력단 페노피브레이트를 함유하는 결핵 치료용 약학 조성물
RU2623876C2 (ru) * 2014-11-10 2017-06-29 Александр Владимирович Диковский Фармацевтическая композиция для лечения гиперлипидемии
KR101512606B1 (ko) 2014-12-11 2015-04-15 (주)이지코스 주름 및 아토피 개선과 피부 보습을 위한 화장료 조성물
CN105853405B (zh) * 2015-01-23 2019-03-08 中国科学院上海药物研究所 苯溴马隆在制备电压门控钾离子通道kcnq激动剂中的应用
EP3277280B1 (en) * 2015-03-31 2023-09-13 Mymd Pharmaceuticals, Inc. Isomyosmine for use in the treatment of autoimmune diseases
EP3095465A1 (en) * 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
KR20180021735A (ko) * 2015-06-15 2018-03-05 바이탈 쎄러피스, 인코포레이티드 항염증성 반응을 유도하기 위한 조성물 및 방법
CN105294672A (zh) * 2015-12-07 2016-02-03 范秀华 一种治疗子宫内膜炎的药物组合物
CN105753826A (zh) * 2016-05-09 2016-07-13 宋晓梅 一种吉非罗齐的药物组合物及其医药用途
CN106074500A (zh) * 2016-07-08 2016-11-09 重庆医药高等专科学校 脱氢洛伐他汀在制备抗炎症性肠病药物中的应用
WO2018064654A1 (en) * 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US20180125795A1 (en) * 2017-01-03 2018-05-10 Thermolife International, Llc Cinnamaldehyde compositions and methods
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ
EP3574892A4 (en) * 2017-06-14 2020-08-12 Bio Solution Co., Ltd. COSMETIC COMPOSITION FOR WRINKLE REDUCTION OR INFLAMMATION PREVENTION WITH THE SUBSTANCE P
CA3068879C (en) * 2017-07-18 2022-12-13 Deyi Pharmaceutical Ltd. Use of cannabidol in treatment of pulmonary hypertension
WO2019018639A1 (en) * 2017-07-19 2019-01-24 Ironwood Pharmaceuticals, Inc. METHOD FOR DETECTION AND QUANTIFICATION OF BILARY ACID IN SALIVA
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
AU2017429312B2 (en) * 2017-08-31 2022-03-24 Hanyi Bio-Technology Company Ltd. Uses of cannabidiol in preparation of drugs for resisting against influenza
CN109419786B (zh) * 2017-08-31 2021-04-30 汉义生物科技（北京）有限公司 大麻二酚在制备抗流感的药物中的用途
SG11202006601VA (en) * 2018-01-12 2020-08-28 Metimedi Pharmaceuticals Co Ltd Methods of treating chronic inflammatory diseases
CN112512519B (zh) * 2018-06-03 2023-09-15 陈文彬 治疗致密化不全心肌症的方法
WO2020061687A1 (en) * 2018-09-28 2020-04-02 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
US20220168325A1 (en) * 2019-03-25 2022-06-02 The University Of Vermont Methods to promote cerebral blood flow in the brain
CN109846885A (zh) * 2019-04-04 2019-06-07 南通大学附属医院 瑞舒伐他汀的新用途
AU2020401838A1 (en) * 2019-12-11 2022-07-21 Ambetex Pty Ltd Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
WO2021215409A1 (ja) 2020-04-20 2021-10-28 株式会社 資生堂 光老化及び／又は真皮色素沈着を予防及び／又は改善する剤，それを用いた美容方法，及びその方法に適用するための美容装置
RU2745687C1 (ru) * 2020-05-19 2021-03-30 Всеволод Иванович Киселев Способ лечения эндометриоза с болевым синдромом и фармацевтическая композиция для его реализации
CN112007165B (zh) * 2020-08-27 2021-10-08 北京大学人民医院 巨噬细胞极化调节剂及其在促进血小板生成中的应用
CN112156089A (zh) * 2020-09-27 2021-01-01 天津国际生物医药联合研究院 苯溴马隆在抗结核分枝杆菌感染中的应用
WO2023058975A1 (ko) * 2021-10-07 2023-04-13 (주)이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
WO2023244738A1 (en) * 2022-06-15 2023-12-21 The Johns Hopkins University Thiazolidinediones for the treatment of muscular dystrophies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
IT1255007B (it) * 1991-07-01 1995-10-11 Altergon Sa Sale solubile dell'ibuprofen c0n n-(2-idrossietil) pirrolidina e composizioni farmaceutiche che li contengono.
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
MXPA01009840A (es) * 1999-03-31 2002-06-21 Abbott Lab Nuevas formulaciones que comprenden agentes reguladores de lipido.
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2431606C (en) * 2000-12-19 2011-07-19 The Board Of Regents Of The University Of Texas System Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
JP2005068060A (ja) * 2003-08-22 2005-03-17 Nrl Pharma Inc ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
CN100486567C (zh) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 姜黄素乳剂及其制备方法
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
WO2008070950A1 (en) * 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
WO2008144355A2 (en) * 2007-05-17 2008-11-27 Morton Grove Pharmaceuticals, Inc. Stable, self-microemulsifying fenofibrate compositions
WO2009033131A2 (en) * 2007-09-07 2009-03-12 Novavax, Inc. Multi-phasic, nano-structured compositions containing a combination of a fibrate and a statin
RU2363451C2 (ru) * 2007-09-14 2009-08-10 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция для приготовления обладающей пролонгированным действием лекарственной формы и способ получения этой формы
WO2009153496A2 (fr) 2008-05-26 2009-12-23 Genfit Composés agonistes ppar, préparation et utilisations
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法

Also Published As

Publication number Publication date
CA2826506A1 (en) 2012-08-09
EP2670390A2 (en) 2013-12-11
SG10201600854SA (en) 2016-03-30
MX2013008850A (es) 2016-09-23
CN103391767B (zh) 2016-08-31
BR112013019732A2 (pt) 2016-10-25
JP6273304B2 (ja) 2018-01-31
EP4397373A3 (en) 2024-09-04
AU2012213218B9 (en) 2017-02-02
CN103391768A (zh) 2013-11-13
RU2013140776A (ru) 2015-03-10
CA2826506C (en) 2017-07-25
AU2012213217A1 (en) 2013-08-15
AU2012213218C1 (en) 2017-04-20
SG192621A1 (en) 2013-09-30
WO2012104654A1 (en) 2012-08-09
CN103391767A (zh) 2013-11-13
ES2981782T3 (es) 2024-10-10
CA2826452C (en) 2016-11-22
ZA201305784B (en) 2014-04-30
BR112013019734A2 (pt) 2016-10-25
RU2013140775A (ru) 2015-03-10
WO2012104655A3 (en) 2013-03-14
JP2014507429A (ja) 2014-03-27
EP3494961B1 (en) 2024-04-10
CN103391768B (zh) 2016-08-10
MX346224B (es) 2017-03-10
JP2016128482A (ja) 2016-07-14
JP2014504629A (ja) 2014-02-24
EP2670389A1 (en) 2013-12-11
ZA201305783B (en) 2014-04-30
BR112013019732B1 (pt) 2023-01-24
NZ711187A (en) 2016-01-29
EP3494961C0 (en) 2024-04-10
SG192620A1 (en) 2013-09-30
NZ613812A (en) 2015-08-28
EP4397373A2 (en) 2024-07-10
EP3494961A1 (en) 2019-06-12
RU2016138830A (ru) 2018-12-12
AU2012213217B2 (en) 2017-04-20
AU2012213218B2 (en) 2017-01-12
RU2635188C2 (ru) 2017-11-09
CA2826452A1 (en) 2012-08-09
NZ613805A (en) 2016-01-29
WO2012104655A2 (en) 2012-08-09
AU2012213218A1 (en) 2013-08-15
MX364229B (es) 2019-04-17

Similar Documents

Publication Publication Date Title
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
MX349004B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
GB201209613D0 (en) New compounds
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
EP2701700A4 (en) PHARMACEUTICAL THERAPY FOR INHIBITING CHEMOTHERAPY-INDUCED SIDE EFFECTS AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING METHOD AND KITS
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX339243B (es) Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
MX348147B (es) Biarilsulfonamidas utiles en el tratamiento de la inflamacion y cancer.
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
PH12020500472A1 (en) Autotaxin inhibitor compounds
IN2013MU03429A (es)

Legal Events

Date Code Title Description
FG Grant or registration